Details for Patent: RE50050

Which drugs does patent RE50050 protect, and when does it expire?

Patent RE50050 protects CAMZYOS and is included in one NDA.

This patent has sixty-seven patent family members in thirty-nine countries.

Summary for Patent: RE50050

Title:	Pyrimidinedione compounds
Abstract:	Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
Inventor(s):	Johan Oslob, Robert Anderson, Danielle Aubele, Marc Evanchik, Jonathan Charles Fox, Brian Kane, Puping Lu, Robert McDowell, Hector Rodriguez, Yonghong Song, Arvinder Sran
Assignee:	Myokardia Inc
Application Number:	US17/699,114
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE50050
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent RE50050

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-001	Apr 28, 2022		RX	Yes	No			Y	Y
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-002	Apr 28, 2022		RX	Yes	Yes			Y	Y
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-003	Apr 28, 2022		RX	Yes	No			Y	Y

International Family Members for US Patent RE50050

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3010910		CR 2023 00034	Denmark
European Patent Office	3010910		301253	Netherlands
European Patent Office	3010910		PA2023535	Lithuania